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Abstract
 
Aims
 
With increasing prevalence of diabetes mellitus and metabolic syndrome (MS), the importance of early detection of
insulin resistance is emphasized. However, a simple and practical method of measurement is not readily available.
Therefore, we examined the sensitivity and specificity of HbA
 
1c
 
 for predicting impaired fasting glucose (IFG) and MS
and its association with cardiovascular risk factors, particularly in the normal range of HbA
 
1c
 
 levels in non-diabetic Korean
subjects.
 
Methods
 
In 40 155 participants (median age 40 years) participating in a medical check-up programme, analysis of the
distribution of HbA
 
1c
 
 and its association with various cardiovascular risk factors was performed. In 22 465 selected
participants, an analysis was conducted of the ability of HbA
 
1c
 
 to predict MS and IFG. Anthropometric measurements
were made in all subjects and fasting glucose, lipid profiles and HbA
 
1c
 
 were measured. The presence of MS was defined
according to the definitions of the Adult Treatment Panel III (ATP III) guideline and the new International Diabetes
Federation (IDF) guideline. Patients with diabetes were excluded from the study.
 
Results
 
The incidence of MS was 12.2% according to ATP III criteria and 7.6% according to IDF criteria. When subjects
were grouped by quartile of HbA
 
1c
 
, cardiovascular risk factors significantly increased as the HbA
 
1c
 
 increased. An HbA
 
1c
 
of 5.45% predicted the presence of MS (ATP III: sensitivity/specificity 57.4/64.3%, area under the curve 64.8%; IDF:
sensitivity 60.2/63.4%, area under the curve 66.1%) and fasting blood glucose 
 
≥
 
 5.6 mmol/l (sensitivity/specificity 53.7/
70%, area under the curve 66.1%). When the analyses were done separately by gender, female subjects showed higher
cut-off of HbA
 
1c
 
 for the prediction of MS (5.55% for both ATP III and IDF criteria).
 
Conclusions
 
HbA
 
1c
 
 increased as cardiovascular risk factors increased and HbA
 
1c
 
 of 5.45% predicted the presence
of MS. HbA
 
1c
 
 might be a predictive measure of IFG and MS, and also cardiovascular risk factors in the Korean
population.
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Introduction
 
Diabetes mellitus affects 5% of the world’s population and its
prevalence is doubling every generation [1]. Between 1996 and
2005, the number of people diagnosed with diabetes in the UK
increased from 1.4 million to 2.1 million, including 1.8 million
diagnosed with Type 2 diabetes. This number has increased
by around 50% in 
 
<
 
 10 years [2]. Diabetes is associated with
many cardiovascular risk factors, which may be present before
the onset of hyperglycaemia or develop after the diagnosis
of diabetes [3,4]. The metabolic syndrome (MS) is a cluster of
various diseases, such as hypertension, obesity, dyslipidaemia
and hyperglycaemia, in which insulin resistance plays a key
pathogenic role, and it has been proposed that this syndrome
is a powerful determinant of diabetes and cardiovascular
disease (CVD) [5–7].
Evidence is accumulating that macrovascular disease is
associated with lesser degrees of hyperglycaemia than micro-
vascular disease [8,9]. The heightened risk of CVD extends to
impaired glucose tolerance (IGT) and, as with diabetes, IGT is
often associated with MS, the components of which explain
some, but not all of the excessive CVD risk seen in IGT and
diabetes [10]. Both IGT and impaired fasting glucose (IFG) are
very strong risk markers for the development of diabetes and
recent reports support the importance of both categories as
risk factors of CVD [11].
Glycated haemoglobin (HbA
 
1c
 
) is widely accepted as a
useful index of mean blood glucose and therapeutic guide-
line of diabetes. HbA
 
1c
 
 may predict incident cardiovascular
events, even in individuals without diabetes mellitus [12–14],
although Blake 
 
et al
 
. have recently reported that the association
of HbA
 
1c
 
 with future cardiovascular risk in women without
diabetes mellitus is largely attributable to a strong correlation
with other cardiovascular risk factors. Thus other proathero-
genic effects of diabetes, rather than levels of glycaemia, might
be related to the vascular complications of diabetes [15].
Recent work suggests the utility of HbA
 
1c
 
 as the predictor of
future risk for diabetes mellitus in diverse ethnic groups [16].
Although there is no doubt that insulin resistance is the
major aetiological factor in the development of MS, direct
quantitative measurement of insulin sensitivity is not readily
available and thus cannot be used as the diagnostic tool for the
syndrome. Thus, various diagnostic criteria for MS have been
suggested [17]. A recent study by Osei 
 
et al
 
. [18] examined
the significance of HbA
 
1c
 
 as a surrogate for MS in high-risk
African-Americans who were genetically predisposed to Type
2 diabetes. They demonstrated that in subjects with increased
HbA
 
1c
 
, some, but not all, components of MS could be defined
by HbA
 
1c
 
. No further research has investigated cut-offs of
HbA
 
1c
 
 in the diagnosis of MS. Therefore, we examined the
association of HbA
 
1c
 
 with the components of MS and
attempted to determine cut-offs of HbA
 
1c
 
 in the diagnosis of
MS in a large non-diabetic Korean population. Our aim was to
determine whether HbA
 
1c
 
 could be used as a simple method to
select those at risk of MS.
 
Patients and methods
 
Patients
 
From participants in the annual medical check-up programme
of the Health Promotion Centre in Kangbuk Samsung Hospital,
Sungkyunkwan University School of Medicine from January to
December 2005, 40 155 subjects were enrolled. Patients with
diabetes mellitus were specifically excluded from the study and
those suspected of having acute inflammatory disease, malignancies
and those taking lipid-lowering medication, antihypertensive
agents or glucose-lowering agents were excluded; 40  155
subjects were included in analysis of the distribution of HbA
 
1c
 
and its association with various cardiovascular risk factors.
Furthermore, we selected 22 465 subjects whose waist circum-
ference data were available for the definition of MS. We
conducted the analysis for the cut-offs for the diagnosis of MS
and IFG.
Data related to smoking, alcohol consumption and exercise
were obtained from self-completed surveys at the time of the
health check-up. Subjects were divided into three groups according
to smoking status: non-smoking, past smoking and current
smoking groups; and into four groups according to drinking
status: non-drinking, 3–4 times per month, 1–2 times per week,
3–4 times per week and 
 
>
 
 5 times per week. Subjects were divided
into three groups according to exercise status: no exercise at all,
less than 3 times a week and more than 3 times a week. The data
were collected from the notes review of the participants and the
protocol was reviewed by the Institutional Review Board of
Kangbuk Samsung Hospital.
 
Anthropometric measurements and blood sampling
 
Height, weight, waist circumference, and systolic and diastolic
blood pressure were measured in duplicate and the results
averaged. Blood pressure was measured with a standardized
sphygmomanometer after at least 5 min of rest, according to
the Hypertension Detection and Follow-up Program protocol.
Body mass index (BMI) was calculated by dividing weight (kg)
by height (m) squared.
After a 12-h fast, blood glucose, total cholesterol, triglyceride,
high-density lipoprotein cholesterol (HDL-C) and low-density
lipoprotein-cholesterol (LDL-C) levels were measured. The
hexokinase method (Advia 1650 Autoanalyser; Bayer Diagnos-
tics, Leverkusen, Germany) was used to measure blood glucose
levels and an enzymatic colorimetric test was used to measure
total cholesterol and triglyceride levels. The selective inhibition
method was used to measure HDL-C and a homogeneous
enzymatic colorimetric test was used to measure LDL-C.
Apoprotein B and Apoprotein A1 were measured on a BN II
system (Dade Behring Co., Marburg, Germany).
HbA
 
1c
 
 was measured by immunoturbidimetric assay with a
Cobra Integra 800 automatic analyser (Roche Diagnostics,
Basel, Switzerland) with a reference value of 4.4–6.4%. The
methodology was aligned with the Diabetes Control and
Complications Trial (DCCT) and National Glycohemoglobin
Standardization Program (NGSP) standards [19]. The intra-
assay coefficient of variation (CV) was 2.3% and interassay CV
was 2.4%, both within the NGSP acceptable limits [20].
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Serum insulin concentration were measured with an immu-
noradiometric assay (INS-Irma; Biosource, Nivelles, Belgium),
with intra- and interassay CVs of 1.6–2.2% (mean serum
concentration 6.6 
 
±
 
 0.1, 53.3 
 
±
 
 0.8 
 
µ
 
IU/ml) and 6.1–6.5%
(mean serum concentration 14.4 
 
±
 
 0.9, 100.4 
 
±
 
 6.1 
 
µ
 
IU/ml),
respectively. As a marker of insulin resistance, homeostatic
model assessment (HOMA)-insulin resistance (IR) was calcu-
lated as follows [21]: HOMA-IR 
 
=
 
 [fasting insulin (
 
µ
 
IU/
ml) 
 
×
 
 fasting glycaemia (mmol/l)]/22.5.
 
Diagnosis of IFG and MS
 
IFG was defined according to newly recommended criteria by
the American Diabetes Association: fasting glucose 
 
≥
 
 5.6 mmol/l
[22].
We applied two different definitions of MS in this popula-
tion: the minor modification version of Third Report National
Cholesterol Education Program Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults
(NCEP-ATP III) guidelines [23] and the newly recommended
guideline by the International Diabetes Federation (IDF) [24].
The NCEP-ATP III definition is satisfied when more than
three of the following five criteria are met:
1. Waist circumference: 
 
≥ 
 
90  cm in men, 
 
≥ 
 
80  cm in women
(defined by the Western Pacific Region of WHO for obesity
(WPRO) criteria [25]).
2. Hypertriglyceridaemia: 
 
≥ 
 
1.7 mmol/l.
3. Low HDL-C: 
 
<
 
  1.0  mmol/l in males and 
 
<
 
 1.3 mmol/l  in
females.
4. Hypertension: 
 
≥ 
 
130/85 mmHg.
5. Fasting hyperglycaemia: 
 
≥
 
 5.6 mmol/l.
According to the new IDF definition, for a person to be defined
as having MS they must have [24] central obesity defined with
ethinicity-specific values (
 
≥
 
 90 cm in men, 
 
≥
 
 80 cm in women)
plus any two of the following four factors:
1. Hypertriglyceridaemia: 
 
≥ 
 
1.7  mmol/l, or specific treatment
for this lipid abnormality.
2. Low HDL-C: 
 
<
 
  1.0  mmol/l in males and 
 
<
 
 1.3 mmol/l  in
females, or specific treatment for this lipid abnormality.
3. Hypertension: 
 
≥ 
 
130/85 mmHg, or treatment of previously
diagnosed hypertension.
4. Fasting hyperglycaemia: 
 
≥
 
 5.6 mmol/l.
 
Statistical methods
 
Results are expressed as median and range, and since no
variables assessed in the study were normally distributed.
Non-parametric tests were used to perform the analysis. The
Kormogorov–Smirnov test was used to test normality.
Comparisons of parameters between groups were made using
Mann–Whitney 
 
U
 
-test and Kruskal–Wallis 
 
H
 
-test, and comparisons
after adjustment for confounding factors were performed using
 
ANCOVA
 
 test. In this study, receiver–operating characteristic
(ROC) curves for predicting IFG and MS were derived by
plotting the sensitivity vs. 1—specificity. The optimal cut-off
point was defined as the closest point on the ROC curve to
the point where 1—specificity was 0 and sensitivity was 100%.
The areas under the curve represent the probability that a
subject chosen at random, who had IFG or MS, had a higher
test value than a subject who did not have IFG or MS. The level
of significance was chosen as 
 
P
 
 
 
<
 
 0.05. All analyses were
carried out with the statistical program SPSS for Windows
v. 12.0 (SPSS Inc., Chicago, IL, USA).
 
Results
 
Of the 40 155 subjects, 24 921 (62.1%) were males and 15 234
(37.9%) females and median age was 40  years (Table  1).
Mean concentration of HbA
 
1c
 
 was 5.32% in men and 5.41%
in women. Of 22 465 subjects whose waist circumference
values were available, 12.2% satisfied the diagnostic criteria
for MS by ATP III criteria and 7.6% by IDF criteria (Table 1).
The mean HbA
 
1c
 
 increased significantly with increasing age
and BMI (Table  2). Non-smokers had higher mean HbA
 
1c
 
compared with past or current smokers and HbA
 
1c
 
 was higher
in those who did not drink alcohol compared with those who
did (Table 2). Similarly, subjects who exercised regularly at
least three times a week had higher mean HbA
 
1c
 
 compared
with those who did not (Table 2).
When the subjects were grouped by quartile of HbA
 
1c
 
,
atherosclerosis risk factors significantly increased as the
HbA
 
1c
 
 increased and HDL-C and Apo A levels decreased as
HbA
 
1c
 
 increased (
 
P 
 
<
 
 0.01) (Table 3). As expected, the largest
Table 1 General characteristics of the study participants
 
 
N = 40 155 Median (range)
Age (years) 40.1 (20–86)
Male (%) 24 921 (62.1)
Fasting blood glucose (mmol/l) 5.2 (3.16–6.94)
HbA1c (%) 5.4 (3.5–7.6)
Total cholesterol (mmol/l) 4.9 (2.17–11.72)
HDL-C (mmol/l) 1.3 (0.52–3.88)
LDL-C (mmol/l) 2.1 (0.01–8.79)
Triglyceride (mmol/l) 2.8 (0.65–55.47)
Uric acid (µmol/l) 321.2 (23.79–713.76)
Hs-CRP (mg/dl) 0.05 (0.02–12.00)
Fasting insulin (µIU/ml) 8.1 (2.08–73.17)
HOMA-IR 1.9 (0.40–18.59)
Apolipoprotein A1 (g/l) 1.4 (0.20–4.88)
Apoliproprotein B (g/l) 0.9 (0.24–2.59)
Systolic blood pressure (mmHg) 110 (70–210)
Diastolic blood pressure (mmHg) 76 (40–130)
Body mass index (kg/m2) 23.4 (14.7–44.2)
Waist circumference (cm) 79.0 (52–136)
Metabolic syndrome (%, N = 22 465)*
By ATP III criteria 2730 (12.2)
By IDF criteria 1704 (7.6)
HDL-C, High-density lipoprotein cholesterol; LDL-C, 
low-density lipoprotein cholesterol; hs-CRP, high-sensitivity 
C-reactive protein; HOMA-IR, homeostasis model 
assessment-insulin resistance.
*The prevalence of metabolic syndrome was analysed only in 
subjects whose waist circumference was available.
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number of subjects with MS by either definition was in the
highest quartile of HbA
 
1c
 
 (Table 3). As in Table 2, more
subjects in the highest quartile of HbA
 
1c
 
 smoked tobacco
and drank alcohol compared with those in the lower quartiles
(Table 3).
An HbA
 
1c
 
 of 5.45% predicted the presence of MS diagnosed
according to the ATP III guideline with a sensitivity of 57.4%
and specificity of 64.3% (area under the curve 64.8%), of MS
according to the IDF guideline with a sensitivity of 60.2% and
specificity of 63.4% (area under the curve 66.1%) and fasting
hyperglycaemia with a sensitivity of 53.7% and specificity of
70% (area under the curve 66.1%) (Table 4).
When the analyses were performed separately according to
gender, the results were different. In male subjects, an HbA
 
1c
 
of 5.45% predicted the presence of MS with a similar specifi-
city and sensitivity to the whole population (Table 4). How-
ever, for IFG an HbA
 
1c
 
 of 5.35% gave higher specificity for
males. For female subjects, an HbA
 
1c
 
 of 5.55% was the
appropriate predictive value for both MS criteria, with both
specificity and sensitivity 
 
>
 
 60%. An HbA
 
1c
 
 of 5.45% was the
most appropriate cut-off for the prediction of IFG in female
subjects (Table 4).
 
Discussion
 
In this large cross-sectional study performed in an Asian
population of relatively pure ethnic background an HbA
 
1c
 
 of
5.45% was the closest value to the point with ideal sensitivity
and specificity for the diagnosis of MS and IFG. Although
HbA
 
1c
 
 is not considered to be a diagnostic criterion for
diabetes or prediabetes, it might provide a simple method of
predicting MS or IFG in a large health screening programme.
Therefore, the results of this study imply that in non-diabetic
Korean subjects with HbA
 
1c
 
 
 
>
 
 5.45%, although the subject is
not within the diagnostic range for diabetes, life style modifi-
cation and education for the future development of diabetes
and MS should be recommended.
HbA
 
1c
 
 is defined as Hb that is irreversibly glycated at one or
both N-terminal valines of the 
 
β
 
-chains according to the new
definition by International Federation of Clinical Chemistry
and it does not exclude haemoglobin that is additionally
glycated at other sites on the 
 
α
 
 or 
 
β
 
 chains [26]. HbA
 
1c
 
 could
reflect universal tissue protein glycation and might be a much
better index of the overall biological effects of glucose above
and beyond its predictive value for the 3-month averages of
Table 2 Distribution of HbA1c in non-diabetic subjects by life-style pattern
 
 
Number Median (range) P-value
By gender Male 24 921 5.3 (3.5–11.0) < 0.01
Female 15 234 5.4 (3.6–8.6)
Total 40 155
By age groups (years) 20–29  734 5.2 (4.0–6.1) < 0.01
30–39 19 094 5.3 (3.5–7.0)
40–49 15 789 5.4 (3.5–8.6)
50–59  3297 5.5 (3.6–7.7)
60–69  1088 5.6 (3.7–11.0)
≥ 70  153 5.6 (4.5–7.1)
Total 40 155
By smoking status Non-smoking 21 381 5.4 (3.5–11.0) < 0.01
Past smoking  6609 5.3 (3.5–8.6)
Current smoking 10 854 5.3 (3.5–7.5)
Total 38 844
By drinking habit Non-drinking 14 085 5.4 (3.5–11.0) < 0.01
≤ 3–4 times per month 10 901 5.3 (3.5–7.5)
1–2 times per week 10 851 5.3 (3.7–8.1)
3–4 times per week  2788 5.3 (3.7–7.4)
≥ 5 times per week  578 5.3 (4.2–7.7)
Total 39 203
Exercise Non-exercise 11 928 5.3 (3.6–7.9) < 0.01
< 3 times per week 13 665 5.3 (3.5–8.0)
≥ 3 time per week 13 593 5.3 (3.8–11.0)
Total 39 186
By BMI (kg/m2) < 18.5  1483 5.3 (4.2–8.1) < 0.01
18.5–22.9 16 663 5.3 (3.5–7.4)
23.0–24.9 10 135 5.4 (3.5–11.0)
≥ 25.0 11 494 5.4 (3.9–8.6)
Total 39 775
Data are given as median with range and number of patients.
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circulating glucose levels [27]. In a nested case–control study
of the Women’s Health Study cohort [15], high baseline HbA
 
1c
 
predicted future cardiovascular events in women without
diabetes mellitus by a factor of 2.25. Osei 
 
et al.
 
 [18] reported
that in 219 non-diabetic, obese, first-degree relatives of
African-American patients with Type 2 diabetes, the upper
tertile of HbA
 
1c
 
 reflected some components of MS. These
results suggest that HbA
 
1c
 
 may be a surrogate marker not only
Table 3 Comparison of cardiovascular risk factors by quartile of HbA1c
 
 
Characteristics
HbA1c quartile 
P-value < 5.1 (n = 10 938) 5.1–5.3 (n = 9668) 5.3–5.5 (n = 12 820) ≥ 5.6 (n = 6729)
Age (years) 38.0 (20–85) 39.0 (20–81) 40.0 (20–86) 42.0 (21–84) < 0.01
Male (%) 7740 (70.8) 6133 (63.4) 7424 (57.9) 3624 (53.9) < 0.01
Fasting blood glucose (mmol/l) 5.1 (3.1–6.9) 5.2 (3.2–6.9) 5.3 (3.8–7.0) 5.5 (2.7–7.0) < 0.01
TC (mmol/l) 4.7 (2.0–9.3) 4.8 (2.2–10.3) 4.9 (2.0–12.1) 5.1 (2.4–12.2) < 0.01
TG (mmol/l) 2.6 (0.6–24.6) 2.6 (0.7–55.5) 2.7 (0.5–53.3) 3.1 (0.6–37.6) < 0.01
HDL-C (mmol/l) 1.3 (0.6–4.0) 1.3 (0.6–3.2) 1.3 (0.6–3.3) 1.3 (0.5–3.4) < 0.01
LDL-C (mmol/l) 2.1 (0.01–6.83) 2.1 (0.01–7.1) 2.2 (0.01–8.8) 2.3 (0.01–8.5) < 0.01
Uric acid (µmol/l) 327.1 (29.7–719.7) 321.2 (35.7–701.9) 315.2 (23.8–666.2) 315.2 (41.6–701.9) < 0.01
Hs-CRP (mg/dl) 0.04 (0.02–9.6) 0.04 (0.02–12.0) 0.05 (0.02–10.2) 0.06 (0.02–4.0) < 0.01
Fasting insulin (µIU/ml) 7.6 (2.1–35.0) 7.8 (2.1–73.2) 8.0 (2.1–134.0) 8.6 (2.3–48.8) < 0.01
HOMA-IR 1.7 (0.4–8.6) 1.8 (0.4–18.6) 1.9 (0.5–32.7) 2.1 (0.5–11.8) < 0.01
Apo A1 (g/l) 1.4 (0.6–3.3) 1.4 (0.2–2.9) 1.39 (0.2–4.9) 1.38 (0.2–3.1)  0.001
Apo B (g/l) 0.9 (0.2–2.1) 0.9 (0.2–2.0) 0.92 (0.2–2.6) 1.0 (0.2–2.0) < 0.01
SBP (mmHg) 110 (70–210) 110 (74–208) 110 (70–260) 110 (70–240) < 0.01
DBP (mmHg) 74 (44–130) 70 (40–130) 70 (44–180) 76 (46–130) < 0.01
BMI (kg/m2) 23.1 (14.7–38.2) 23.1 (13.4–37.5) 23.3 (14.7–44.2) 24.1 (15–41.8) < 0.01
WC (cm) 78 (54–109) 78 (53–115) 79 (52–136) 81 (52–120) < 0.01
Current smokers (%)* 3236 (30.3) 2672 (28.5) 3309 (26.7) 1637 (25.7) < 0.01
Current drinkers (%)* 7619 (79.0) 6248 (65.8) 7624 (60.9) 3627 (56.1) < 0.01
Regular exercise (%)*† 3571 (33.3) 3296 (34.8) 4416 (35.3) 2310 (35.8) < 0.01
Metabolic syndrome (%)‡
ATP III criteria 407 (7.3) 465 (8.7) 860 (11.7) 998 (24.0) < 0.01
IDF criteria 230 (4.1) 264 (4.9) 556 (7.6) 654 (15.7) < 0.01
HDL-C, High-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; 
HOMA-IR, homeostasis model assessment-insulin resistance.
Data are given as median with range and number of patients.
*Proportions were analysed in subjects with available data.
†Regular exercise at least three times a week.
‡The prevalences of metabolic syndrome were analysed only in subjects whose waist circumference values were available.
All significant differences of the continuous variables between HbA1c quartile were consistent even after adjustment for age, 
BMI and gender by ANCOVA test.
Table 4 ROC curve of HbA1c to predict impaired fasting glucose and metabolic syndrome by two criteria
 
 
Cut-offs
(%)
Sensitivity/specificity (%) 
Total Male Female 
ATP III IDF IFG ATP III IDF IFG ATP III IDF IFG
5.35 68.1/51.2 71.0/50.5 65.2/56.9 64.9/55.9 68.4/54.9 61.7/63.1 79.8/44 78.5/43.5 75.1/48.3
5.45 57.4/64.3 60.2/63.4 53.7/70.0 53.4/68.7 56.5/67.5 49.9/75.8 72.4/57.5 70.9/56.9 64.3/62
5.55 47.5/75.2 49.9/74.3 42.8/80.6 42.6/78.9 45.1/77.5 38.8/85.2 65.2/69.7 63.8/69 53.9/74.1
5.65 36.6/84 38.4/83.1 32.6/88.6 32.1/86.4 33.8/85.3 29.0/91.7 52.9/80.2 51.7/79.6 42.4/84.3
AUC 64.8 66.1 66.1 64.8 66.0 67.3 71.9 70.4 68.9
ROC, Receiver–operator curve; ATP, Adult Treatment Panel; IDF, diagnostic criteria for metabolic syndrome from International Diabetes 
Federation; IFG, impaired fasting glucose; AUC, area under the curve (95% confidence interval).
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of future diabetes, but also of CVD. Although there are many
studies which report the utility of HbA1c in predicting CVD
and diabetes, there are few which investigate the usefulness of
HbA1c as a predictor of MS.
In our result, an HbA1c of 5.45% was the most appropriate
cut-off for MS, defined by both ATP III and IDF guidelines,
with the best balance between sensitivity and specificity, at
least in this studied population. This level of HbA1c also
predicted fasting hyperglycaemia (> 5.6 mmol/l). HbA1c has
been considered a very convenient and practical screening tool
for high-risk populations for primary diabetes and cardiovas-
cular prevention programmes [28]. Our results could be tested
prospectively in long-term studies in other ethnic populations
at high risk of developing Type 2 diabetes and MS. Prior
mortality studies [12–14] in populations mainly without
diabetes mellitus have suggested that the predictive value of
HbA1c persists in adjusted analyses. Potential differences in
study design that may partly account for these disparities
include gender differences and the use of different HbA1c
assays. However, the predictive value of HbA1c in these studies
was largely attributable to its association with other risk factors.
Another interesting result of our analyses was that the
predictive value of HbA1c for MS and IFG was dependent on
gender, i.e. in female subjects the HbA1c cut-off with the
appropriate specificity and sensitivity was higher than in male
subjects. There are few comparable data, but HbA1c might
vary by gender, so that cut-offs should be determined
separately for men and women. Our study suggests that female
Korean subjects are at lower risk of MS than male Korean
subjects. However, our results could have arisen from the
skewed data of this population, because the baseline level of
HbA1c was higher in female subjects. This issue must be clari-
fied in a different population of either the same or different
ethnic background.
In this study, HOMA-IR increased with increasing quartile
of HbA1c. Although insulin resistance is regarded as the
aetiological mechanism underpinning MS, direct quantifica-
tion of insulin sensitivity can be difficult and complex in the
general population. Simple measures, such as fasting serum
insulin, have been used as a surrogate of insulin resistance in
previous epidemiological studies. The present data suggest
that HbA1c could be a marker not just for glucose, but also for
detection of insulin resistance, such as in MS, as HOMA-IR
showed a significant correlation with HbA1c (correlation
coefficient = 0.157, P < 0.01).
In this study, current smokers and alcohol drinkers had
lower HbA1c compared with those who did not smoke or
drink. This discrepancy is probably due to the exclusion of
subjects with diabetes from the study population, so that
smokers and drinkers with high HbA1c might have had diabe-
tes and have been excluded. Furthermore, those who exercised
more than three times a week had higher HbA1c compared
with subjects who did not exercise regularly. The reason for
this discrepancy might be explained by the observation that
subjects who exercised regularly had a higher BMI than
non-exercisers: those with higher HbA1c also had a higher BMI
and might have exercised more deliberately than those subjects
with lower HbA1c and lower BMI.
Our study has several limitations. First, it was a cross-
sectional study, so that a definite relationship between HbA1c
and MS cannot be assumed. Further research in a more diverse
ethnic group must be done to clarify the relationship. Second,
as this study was performed in non-diabetic subjects, bias
might have arisen from the distribution of the metabolic
parameters. Third, the non-diabetic reference interval of
HbA1c in the method used was 4.4–6.4%. However, these
values were not based on data from the same population as the
participants of the study, but were provided by the manufac-
turer. Despite these limitations, this is the first study in this
field and included a large study population.
In conclusion, HbA1c may be used as a predictor for fasting
hyperglycaemia and MS. An HbA1c of 5.45% seemed to
provide the best balance between sensitivity and specificity for
detecting MS in this population. Increasing HbA1c was
associated with increasing cardiovascular risk factors, so that
HbA1c might be predictive of the future development of
cardiovascular risk factors. These data support the need for a
prospective study examining levels of HbA1c and future
cardiovascular risk and the metabolic syndrome.
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